Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy.

ABSTRACT: OBJECTIVES:Pompe disease is a progressive metabolic myopathy for which enzyme replacement therapy (ERT) was approved in 2006. While various publications have examined the effects of ERT in classic-infantile patients and in adults, little has been published on ERT in children with non-classic presentations. STUDY DESIGN:This prospective study was conducted from June 1999 to May 2015. Seventeen patients from various countries participated. Outcome measures comprised muscle function (6-minute walk test, quick motor-function test (QMFT)), muscle strength (hand-held dynamometry; manual muscle testing), and lung function (FVC sitting and supine). For each outcome measure, we used linear mixed-effects models to calculate the difference at group level between the start of therapy and 7 years of ERT. Patients' individual responses over time were also evaluated. RESULTS:Eleven males and six females started ERT at ages between 1.1 and 16.4 years (median 11.9 years); 82% of them carried the common c.-32-13T?>?G GAA gene variant on one allele. At group level, distance walked increased by 7.4 percentage points (p?

SUBMITTER: van der Meijden JC 

PROVIDER: S-EPMC6326992 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature